TherapeuticsMD, Inc. Accounts Receivable
TherapeuticsMD, Inc. (TXMD) had Accounts Receivable of $32.16 million as of 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2022-11-14
- 2022-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $32.16M.
- 2022-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $45.80M.
- 2022-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $35.41M.
- 2021-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $36.18M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current | Accounts Receivable, after Allowance for Credit Loss, Current as first filed |
|---|---|---|
| 2022-09-30 | $32.16M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $45.80M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $35.41M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $36.18M 10-Q · filed 2022-11-14 | |
| 2021-09-30 | $37.40M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $33.48M 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $33.72M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $32.38M 10-K · filed 2022-03-23 | $32.38M 10-K · filed 2021-03-04 |
| 2020-09-30 | $24.06M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $18.29M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $20.66M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $24.40M 10-K · filed 2021-03-04 | |
| 2019-09-30 | $15.32M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $18.38M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $14.94M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $11.06M 10-K · filed 2020-02-24 | |
| 2018-09-30 | $12.80M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $5.63M 10-Q · filed 2018-07-30 | |
| 2018-03-31 | $5.10M 10-Q · filed 2018-05-07 | |
| 2017-12-31 | $4.33M 10-K · filed 2019-02-27 | |
| 2017-09-30 | $4.39M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $3.40M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $3.92M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $4.50M 10-K · filed 2018-02-23 | |
| 2016-09-30 | $5.03M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $4.48M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $5.06M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $3.05M 10-K · filed 2017-02-28 | |
| 2015-09-30 | $3.67M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $3.31M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $2.64M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $2.15M 10-K · filed 2016-02-26 | |
| 2014-09-30 | $2.15M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $2.16M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $2.34M 10-Q · filed 2014-05-07 | |
| 2013-12-31 | $1.69M 10-K · filed 2015-03-12 | |
| 2013-09-30 | $1.79M 10-Q · filed 2013-11-05 | |
| 2013-06-30 | $957.78K 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $602.82K 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $714.42K 10-K · filed 2014-03-05 | $606.64K 10-K · filed 2013-03-12 |
| 2012-09-30 | $270.26K 10-Q · filed 2012-11-13 | |
| 2012-06-30 | $407.93K 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $112.05K 10-Q · filed 2012-05-11 | |
| 2011-12-31 | $26.72K 10-K · filed 2013-03-12 | |
| 2011-09-30 | $2.10K 10-Q · filed 2011-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |